abstract: UNASSIGNED: @entity2 ( @entity2 ) is the most common form of @entity3 in the elderly. The recent evidence in @entity2 research suggests that alterations in the microRNA (miRNA) could contribute to risk for the disease. However, little is understood about the roles of miRNAs in @entity1 of early @entity2 ( @entity2 ). Here, we used 5-month-old APP/ @entity4 @entity0 , which mimic many of the salient features of the early stage of @entity2 pathological process, to further investigate the roles of miRNAs in synaptic loss involved in learning and memory. We used miRNA expression microarrays on RNA extracted from the hippocampus of 5-month-old APP/ @entity4 @entity0 and wild type @entity0 . Real-time reverse transcription PCR was conducted to verify the candidate miRNAs discovered by microarray analysis. The data showed that @entity5 was increased significantly in the hippocampus of 5-month-old APP/ @entity4 @entity0 , which were concomitant with that APP/ @entity4 @entity0 at the same age displayed a significant synaptic loss and @entity1 . Bioinformatic analysis predicted that neuritin ( @entity6 ) mRNA is targeted by @entity5 . Overexpression of @entity5 lowers the levels of neuritin and synaptic proteins expression in primary hippocampal neurons damage induced by Ab25-35. And the expression of @entity5 was also up-regulated in the hippocampal neurons from APP/ @entity4 @entity0 compared with WT littermates. In contrast, suppression of @entity5 by @entity5 inhibitor significantly results in higher levels of neuritin and synaptic proteins expression. Taken together, @entity5 is involved in @entity1 in 5-month-old APP/ @entity4 @entity0 through regulation of neuritin.

title: MicroRNA-574 is involved in @entity1 in 5-month-old APP/ XXXX @entity0 through regulation of neuritin.

answer: @entity4


abstract: UNASSIGNED: @entity2 ( @entity2 ) is the most common form of @entity3 in the elderly. The recent evidence in @entity2 research suggests that alterations in the microRNA (miRNA) could contribute to risk for the disease. However, little is understood about the roles of miRNAs in @entity1 of early @entity2 ( @entity2 ). Here, we used 5-month-old APP/ @entity4 @entity0 , which mimic many of the salient features of the early stage of @entity2 pathological process, to further investigate the roles of miRNAs in synaptic loss involved in learning and memory. We used miRNA expression microarrays on RNA extracted from the hippocampus of 5-month-old APP/ @entity4 @entity0 and wild type @entity0 . Real-time reverse transcription PCR was conducted to verify the candidate miRNAs discovered by microarray analysis. The data showed that @entity5 was increased significantly in the hippocampus of 5-month-old APP/ @entity4 @entity0 , which were concomitant with that APP/ @entity4 @entity0 at the same age displayed a significant synaptic loss and @entity1 . Bioinformatic analysis predicted that neuritin ( @entity6 ) mRNA is targeted by @entity5 . Overexpression of @entity5 lowers the levels of neuritin and synaptic proteins expression in primary hippocampal neurons damage induced by Ab25-35. And the expression of @entity5 was also up-regulated in the hippocampal neurons from APP/ @entity4 @entity0 compared with WT littermates. In contrast, suppression of @entity5 by @entity5 inhibitor significantly results in higher levels of neuritin and synaptic proteins expression. Taken together, @entity5 is involved in @entity1 in 5-month-old APP/ @entity4 @entity0 through regulation of neuritin.

title: MicroRNA-574 is involved in @entity1 in 5-month-old APP/ @entity4 XXXX through regulation of neuritin.

answer: @entity0


abstract: BACKGROUND: To assess the efficacy and @entity2 of combined @entity10 with @entity8 (LP) as a first line chemotherapy in @entity3 . METHODS: The clinical data of 45 @entity0 with @entity9 treated initially with @entity10 - @entity8 chemotherapy were collected and reviewed retrospectively. The overall response, treatment @entity2 and @entity7 relief were analyzed with SPSS software. RESULTS: The overall response rate was 42.2%, with 1 @entity0 (2.2%) showing complete remission, 18 @entity0 (40.0%) with partial remission, 19 (42.2%) with @entity1 ( @entity1 ), and 7 (15.6%) with progressive disease, respectively. The most common hematological @entity2 was @entity6 with grade 0, I, II, III and IV in 16 (35.6%), 10 (22.2%), 11 (24.4%), 7 (15.6%), and 1 @entity0 (2.2%), respectively. Thirty-seven @entity0 (82.2%) experienced @entity5 without grade III-IV instances occurring. Four @entity0 (8.9%) experienced grade I hepatotoxicity. No nephrotoxicity was observed. Five in thirteen @entity0 treated with concurrent chemoradiotherapy (CRT) suffered severe @entity4 . The @entity7 resolved or improved in 32 @entity0 (71%). CONCLUSIONS: @entity10 - @entity8 showed a significant antitumor effect to squamous @entity3 with manageable @entity2 . Limitation of the surveillance time and the retrospective nature, the effect that based on these data formal prospective trials appear warranted and are needed prior to routine first line use of this regimen.

title: The efficacy and XXXX of combined @entity10 with @entity8 as a first-line chemotherapy for advanced @entity9 .

answer: @entity2


abstract: BACKGROUND: To assess the efficacy and @entity2 of combined @entity10 with @entity8 (LP) as a first line chemotherapy in @entity3 . METHODS: The clinical data of 45 @entity0 with @entity9 treated initially with @entity10 - @entity8 chemotherapy were collected and reviewed retrospectively. The overall response, treatment @entity2 and @entity7 relief were analyzed with SPSS software. RESULTS: The overall response rate was 42.2%, with 1 @entity0 (2.2%) showing complete remission, 18 @entity0 (40.0%) with partial remission, 19 (42.2%) with @entity1 ( @entity1 ), and 7 (15.6%) with progressive disease, respectively. The most common hematological @entity2 was @entity6 with grade 0, I, II, III and IV in 16 (35.6%), 10 (22.2%), 11 (24.4%), 7 (15.6%), and 1 @entity0 (2.2%), respectively. Thirty-seven @entity0 (82.2%) experienced @entity5 without grade III-IV instances occurring. Four @entity0 (8.9%) experienced grade I hepatotoxicity. No nephrotoxicity was observed. Five in thirteen @entity0 treated with concurrent chemoradiotherapy (CRT) suffered severe @entity4 . The @entity7 resolved or improved in 32 @entity0 (71%). CONCLUSIONS: @entity10 - @entity8 showed a significant antitumor effect to squamous @entity3 with manageable @entity2 . Limitation of the surveillance time and the retrospective nature, the effect that based on these data formal prospective trials appear warranted and are needed prior to routine first line use of this regimen.

title: The efficacy and @entity2 of combined @entity10 with @entity8 as a first-line chemotherapy for advanced XXXX .

answer: @entity9


abstract: BACKGROUND: To assess the efficacy and @entity2 of combined @entity10 with @entity8 (LP) as a first line chemotherapy in @entity3 . METHODS: The clinical data of 45 @entity0 with @entity9 treated initially with @entity10 - @entity8 chemotherapy were collected and reviewed retrospectively. The overall response, treatment @entity2 and @entity7 relief were analyzed with SPSS software. RESULTS: The overall response rate was 42.2%, with 1 @entity0 (2.2%) showing complete remission, 18 @entity0 (40.0%) with partial remission, 19 (42.2%) with @entity1 ( @entity1 ), and 7 (15.6%) with progressive disease, respectively. The most common hematological @entity2 was @entity6 with grade 0, I, II, III and IV in 16 (35.6%), 10 (22.2%), 11 (24.4%), 7 (15.6%), and 1 @entity0 (2.2%), respectively. Thirty-seven @entity0 (82.2%) experienced @entity5 without grade III-IV instances occurring. Four @entity0 (8.9%) experienced grade I hepatotoxicity. No nephrotoxicity was observed. Five in thirteen @entity0 treated with concurrent chemoradiotherapy (CRT) suffered severe @entity4 . The @entity7 resolved or improved in 32 @entity0 (71%). CONCLUSIONS: @entity10 - @entity8 showed a significant antitumor effect to squamous @entity3 with manageable @entity2 . Limitation of the surveillance time and the retrospective nature, the effect that based on these data formal prospective trials appear warranted and are needed prior to routine first line use of this regimen.

title: The efficacy and @entity2 of combined XXXX with @entity8 as a first-line chemotherapy for advanced @entity9 .

answer: @entity10


abstract: BACKGROUND: To assess the efficacy and @entity2 of combined @entity10 with @entity8 (LP) as a first line chemotherapy in @entity3 . METHODS: The clinical data of 45 @entity0 with @entity9 treated initially with @entity10 - @entity8 chemotherapy were collected and reviewed retrospectively. The overall response, treatment @entity2 and @entity7 relief were analyzed with SPSS software. RESULTS: The overall response rate was 42.2%, with 1 @entity0 (2.2%) showing complete remission, 18 @entity0 (40.0%) with partial remission, 19 (42.2%) with @entity1 ( @entity1 ), and 7 (15.6%) with progressive disease, respectively. The most common hematological @entity2 was @entity6 with grade 0, I, II, III and IV in 16 (35.6%), 10 (22.2%), 11 (24.4%), 7 (15.6%), and 1 @entity0 (2.2%), respectively. Thirty-seven @entity0 (82.2%) experienced @entity5 without grade III-IV instances occurring. Four @entity0 (8.9%) experienced grade I hepatotoxicity. No nephrotoxicity was observed. Five in thirteen @entity0 treated with concurrent chemoradiotherapy (CRT) suffered severe @entity4 . The @entity7 resolved or improved in 32 @entity0 (71%). CONCLUSIONS: @entity10 - @entity8 showed a significant antitumor effect to squamous @entity3 with manageable @entity2 . Limitation of the surveillance time and the retrospective nature, the effect that based on these data formal prospective trials appear warranted and are needed prior to routine first line use of this regimen.

title: The efficacy and @entity2 of combined @entity10 with XXXX as a first-line chemotherapy for advanced @entity9 .

answer: @entity8


abstract: BACKGROUND: Three-dimensional (3D) vision systems are now available for thoracic surgery. It is unclear whether 3D video-assisted thoracic surgery (VATS) is superior to 2D VATS systems. This study aimed to compare the operative and perioperative data between 2D and 3D VATS lobectomy (VTL) and to identify the actual role of 3D VTL in thoracic surgery. METHODS: A two-institutional comparative study was conducted from November 2013 to November 2014 at Liaoning Cancer Hospital _ Institute and the First Affiliated Hospital of Guangzhou Medical University, China, of 300 @entity0 with resectable @entity3 ( @entity3 ). @entity0 were assigned to receive either the 3D VATS (n=150) or 2D VATS (n=150) lobectomy. The operative and perioperative data between 2D VATS and 3D VATS were compared. RESULTS: Although there was no significant difference between the two groups regarding the incidence of each single complication, a significantly less operative time was found in the 3D VATS group (145 min) than in the 2D VATS group (176 min) (P=0.006). Postoperative mortality rates in 3D VATS and 2D VATS groups were both 0%.No significant difference was found between groups for estimated @entity1 (P=0.893), chest drainage tube placement time (P=0.397), length of hospital stay (P=0.199), number of lymph nodes resected (P=0.397), @entity2 (P=0.882) and cost of care (P=0.913). CONCLUSIONS: Early results of this study demonstrate that the 3D VATS lobectomy procedure can be performed with less operative time. 3D VATS and 2D VATS lobectomy are both safe procedures in first-line surgical treatment of @entity3 .

title: A comparative analysis of lung cancer XXXX treated with lobectomy via three-dimensional video-assisted thoracoscopic surgery versus two-dimensional resection.

answer: @entity0


abstract: UNASSIGNED: We report a case of Grade 3 radiation @entity9 after administration of a combination of @entity11 , @entity8 , and bevacizumab, following irradiation for a locally advanced cervical @entity2 . A 50-year-old @entity0 was diagnosed with an FIGO Stage IIIb @entity5 of the cervix with bilateral pelvic and para-aortic lymph nodes.  She underwent concurrent chemoradiation followed by @entity6 ( @entity6 ) intracavitary brachytherapy. She had a complete loco-regional response.  A supraclavicular recurrence was diagnosed three months after completing treatment and two cycles of @entity11 , @entity7 , and bevacizumab were given in April 2014.  Shortly after the second cycle, she was admitted to the hospital for significant @entity4 , @entity3 followed by symptoms of bowel subocclusion.  The CT scan and endoscopic images revealed thickening of the sigmoid wall with important @entity1 and @entity12 . The biopsy was consistent with acute radiation-induced @entity10 .  Because of persistent digestive symptoms, a diverting ileostomy was done few months later.  The location, timing, pathology, and its association with a  high-dose region are analyzed in this case report.

title: Grade 3 Radiation Recall XXXX after Treatment for Locally Advanced @entity2 : A Case Report.

answer: @entity9


abstract: UNASSIGNED: We report a case of Grade 3 radiation @entity9 after administration of a combination of @entity11 , @entity8 , and bevacizumab, following irradiation for a locally advanced cervical @entity2 . A 50-year-old @entity0 was diagnosed with an FIGO Stage IIIb @entity5 of the cervix with bilateral pelvic and para-aortic lymph nodes.  She underwent concurrent chemoradiation followed by @entity6 ( @entity6 ) intracavitary brachytherapy. She had a complete loco-regional response.  A supraclavicular recurrence was diagnosed three months after completing treatment and two cycles of @entity11 , @entity7 , and bevacizumab were given in April 2014.  Shortly after the second cycle, she was admitted to the hospital for significant @entity4 , @entity3 followed by symptoms of bowel subocclusion.  The CT scan and endoscopic images revealed thickening of the sigmoid wall with important @entity1 and @entity12 . The biopsy was consistent with acute radiation-induced @entity10 .  Because of persistent digestive symptoms, a diverting ileostomy was done few months later.  The location, timing, pathology, and its association with a  high-dose region are analyzed in this case report.

title: Grade 3 Radiation Recall @entity9 after Treatment for Locally Advanced XXXX : A Case Report.

answer: @entity2


abstract: @entity6 ( @entity6 ) is caused by an @entity4 on pancreatic beta cells that leads to @entity5 . The incidence of @entity6 in Australia has doubled over the past 20 years. @entity6 treatment focuses on physiological insulin replacement, aiming for near-normal blood @entity3 levels. Hypoglycaemia is a significant cause of morbidity and mortality in @entity6 . Optimal @entity6 management is complex, and is enhanced by empowering individuals in all aspects of managing @entity1 . New technologies, including insulin pumps, continuous @entity3 monitors and sensor-augmented pumps, can assist @entity0 achieve better glycaemic control and reduce the risk of severe hypoglycaemia. @entity0 with @entity6 can achieve significantly better outcomes during pregnancy and for their @entity0 by planning for their pregnancy and by intensive glycaemic control. Several trials are underway that seek to identify the determinants of autoimmunity and to develop therapies that prevent @entity6 in at-risk individuals. Pancreatic and islet cell transplants are proven therapies, but are only offered to individuals with @entity1 and @entity2 (pancreas) or severe hypoglycaemia unawareness (islet cell transplants). Although @entity6 is still associated with considerable premature mortality, recent findings show that a significant improvement in life expectancy has occurred.

title: Recent advances in type 1 XXXX .

answer: @entity1


abstract: OBJECTIVE: @entity3 ( @entity3 ) is characterized by involuntary, irregular clonic or tonic movement of muscles innervated by the facial nerve. We evaluated structural reorganization in brain gray matter and white matter and whether neuroplasticity is linked to clinical features in @entity3 @entity0 . METHODS: High-resolution structural magnetic resonance imaging and diffusion tensor imaging data were acquired by 3.0T MRI from 42 @entity0 with @entity3 and 30 healthy subjects. The severity of the @entity5 was assessed according to @entity1 rating scale. Voxel-based morphometry (VBM) and tract-based spatial statistics (TBSS) analysis were performed to identify regional grey matter volume (GMV) changes and whole-brain microstructural integrity disruption measured by fractional anisotropy (FA), @entity4 ( @entity4 ), axial diffusivity (AD) and radial diffusivity (RD). RESULTS: The VBM analysis showed that @entity0 with @entity3 reduced GMV in the right inferior parietal lobule and increased GMV in the cerebellar lobule @entity2 , when compared with healthy subjects. Furthermore, within the @entity3 disease group, GMV decreased with the disease duration in the right inferior parietal lobule. TBSS did not identify group differences in diffusivity parameters. CONCLUSIONS: While no white matter integrity disruption was detected in the brain of @entity0 with @entity3 , our study identified evident GMV changes in brain areas which were known to be involved in motor control. SIGNIFICANCE: Our results suggest that @entity3 , a chronic neurovascular conflict disease, is related to structural reorganization in the brain.

title: Structural brain alterations in hemifacial XXXX : A voxel-based morphometry and diffusion tensor imaging study.

answer: @entity5


abstract: UNASSIGNED: Tolerance refers to the diminished effect of a drug following its repeated administration such that a larger dose is needed to obtain the initial effect. Tolerance to a drug's effects on operant behavior is more likely to develop when initial drug administration results in a loss of reinforcement. It remains unknown how offsetting loss of reinforcement influences the development of tolerance. Providing extra (non-contingent) food pellets was hypothesized to impede the development of tolerance to effects of a repeatedly administered dose of @entity1 that reduced the number of food pellets earned by @entity0 . A multiple schedule with two variable-interval (VI) 60-s components resulting in food delivery was used to maintain lever pressing. Extra food pellets were provided in one of those components according to a variable-time (VT) 120-s or a VT 30-s schedule for separate groups of @entity0 (n=6 for each group). Effects of @entity1 (0.1-3.0mg/kg) were tested before (acute) and during (chronic) injections (45days) of an individually selected, repeatedly administered dose that reduced the number of food pellets earned by at least 50% compared to when saline was tested acutely. There was a dose-dependent decrease in lever-press rates and food pellets earned. The development of tolerance was quantified by dividing the area-under-the-curve (AUC) of the chronic dose-effect function by the AUC of the acute dose-effect function. Tolerance developed to a similar extent in components with and without extra food pellets for @entity0 in both groups. These results indicate that offsetting reinforcement loss, at least as studied here, did not differentially affect tolerance development.

title: Extra (non-contingent) food does not affect behavioral tolerance to XXXX 's rate-decreasing effects.

answer: @entity1


abstract: BACKGROUND: Pre-clinical research has shown b2 -adrenoceptors to be essential for the antiallodynic action of antidepressant drugs in @entity2 models of @entity1 and that sustained treatment with b2 -agonists has an antiallodynic action. Here, we clinically investigated whether chronic b2 -agonist treatments may influence the incidence of post-thoracotomy @entity5 , @entity3 that recurs or persists along a thoracotomy scar more than 2  months after surgery, either @entity4 . METHODS: We conducted an epidemiological study on @entity0 operated by thoracotomy. Demographic data, medical history and treatments concomitant to the surgery were recorded at a follow-up visit. Information on perioperative treatments was collected from the anaesthesia records and confirmed by the @entity0 . In @entity0 with @entity3 at the surgery level, post-thoracotomy @entity5 was assessed by clinical examination and numeric scale. Physical examination and @entity6 questionnaire were used to discriminate @entity1 at scar level. RESULTS: One hundred and eighty-nine @entity0 were included. Eighty-one @entity0 reported persisting @entity3 , with neuropathic characteristics in 58 of them (30% of the 189 @entity0 ). The most common chronic drugs during the perioperative period were inhaled b2 -agonists (28.6%). The chronic use of b2 -agonists was an independent predictor of thoracic @entity1 (but not of @entity1 ) and was associated with a five-fold decrease in the relative incidence of @entity1 [OR  =  0.19 (0.06-0.45)]. CONCLUSIONS: These data suggest a possible influence of chronic b2 -agonist treatments on @entity1 secondary to thoracotomy. This apparent preventive effect of b2 -agonist treatments should warrant controlled clinical trials.

title: Effects of b2 agonists on post-thoracotomy XXXX incidence.

answer: @entity3


abstract: UNASSIGNED: In this study we demonstrated that the vaccine candidate against avian influenza virus H5N1 based on the hemagglutinin H5 (HA) fused to the @entity1 @entity3 ( @entity4 ) can also be used for differentiating infected from vaccinated animals (DIVA). As the strategy of DIVA requires at least two proteins, we obtained a variant of the nucleoprotein (NP49-375) in @entity0 . After its purification by IMAC, the competence of the proteins NP49-375 and @entity4 as coating antigens in indirect ELISA assays were tested by using the sera of @entity1 immunized with the proteins HA and @entity4 and the reference sera from several avian influenza subtypes. Together with these sera, the sera from different species of birds and the sera of @entity1 infected with other avian @entity2 were analyzed by competition ELISA assays coated with the proteins NP49-375 and @entity4 . The results showed that the segment @entity3 in the chimeric protein @entity4 did not interfere with the recognition of the molecule HA by its specific antibodies. Also, we observed variable detection levels when the reference sera were analyzed in the ELISA plates coated with the protein NP49-375. Moreover, only the antibodies of the reference serum subtype H5 were detected in the ELISA plates coated with the protein @entity4 . The competition ELISA assays showed percentages of inhibition of 88-91% for the positives sera and less than 20% for the negative sera. We fixed the cut-off value of these assays at 25%. No antibody detection was observed in the sera from different species of birds or the sera of @entity1 infected with other avian @entity2 . This study supported the fact that the ELISA assays using the proteins NP49-375 and @entity4 could be valuable tools for avian influenza surveillance and as a strategy of DIVA for counteracting the highly pathogenic avian influenza virus H5N1 outbreaks.

title: Dual function of the hemagglutinin H5 fused to @entity1 XXXX in a potential strategy of DIVA against avian influenza disease: preliminary study.

answer: @entity3


abstract: UNASSIGNED: In this study we demonstrated that the vaccine candidate against avian influenza virus H5N1 based on the hemagglutinin H5 (HA) fused to the @entity1 @entity3 ( @entity4 ) can also be used for differentiating infected from vaccinated animals (DIVA). As the strategy of DIVA requires at least two proteins, we obtained a variant of the nucleoprotein (NP49-375) in @entity0 . After its purification by IMAC, the competence of the proteins NP49-375 and @entity4 as coating antigens in indirect ELISA assays were tested by using the sera of @entity1 immunized with the proteins HA and @entity4 and the reference sera from several avian influenza subtypes. Together with these sera, the sera from different species of birds and the sera of @entity1 infected with other avian @entity2 were analyzed by competition ELISA assays coated with the proteins NP49-375 and @entity4 . The results showed that the segment @entity3 in the chimeric protein @entity4 did not interfere with the recognition of the molecule HA by its specific antibodies. Also, we observed variable detection levels when the reference sera were analyzed in the ELISA plates coated with the protein NP49-375. Moreover, only the antibodies of the reference serum subtype H5 were detected in the ELISA plates coated with the protein @entity4 . The competition ELISA assays showed percentages of inhibition of 88-91% for the positives sera and less than 20% for the negative sera. We fixed the cut-off value of these assays at 25%. No antibody detection was observed in the sera from different species of birds or the sera of @entity1 infected with other avian @entity2 . This study supported the fact that the ELISA assays using the proteins NP49-375 and @entity4 could be valuable tools for avian influenza surveillance and as a strategy of DIVA for counteracting the highly pathogenic avian influenza virus H5N1 outbreaks.

title: Dual function of the hemagglutinin H5 fused to XXXX @entity3 in a potential strategy of DIVA against avian influenza disease: preliminary study.

answer: @entity1


abstract: Objective measures of @entity0 gait quality via force plates, pressure mats or kinematic analysis are considered superior to subjective gait assessment (SGA). Despite research demonstrating that SGA does not accurately detect @entity1 , it remains the most commonly performed diagnostic test for detecting @entity1 in @entity0 . This is largely because the financial, temporal and spatial requirements for existing objective gait analysis equipment makes this technology impractical for use in general practice. The utility of slow motion video as a potential tool to augment SGA is currently untested. To evaluate a more accessible way to overcome the limitations of SGA, a slow motion video study was undertaken. Three experienced veterinarians reviewed video footage of 30 @entity0 , 15 with a diagnosis of primary limb @entity1 based on history and physical examination, and 15 with no indication of limb @entity1 based on history and physical examination. Four different videos were made for each @entity0 , demonstrating each @entity0 walking and trotting in real time, and then again walking and trotting in 50% slow motion. For each video, the veterinary raters assessed both the degree of @entity1 , and which limb(s) they felt represented the source of the @entity1 . Spearman's rho, Cramer's V, and t-tests were performed to determine if slow motion video increased either the accuracy or consistency of raters' SGA relative to real time video. Raters demonstrated no significant increase in consistency or accuracy in their SGA of slow motion video relative to real time video. Based on these findings, slow motion video does not increase the consistency or accuracy of SGA values. Further research is required to determine if slow motion video will benefit SGA in other ways.

title: Effectiveness of slow motion video compared to real time video in improving the accuracy and consistency of subjective gait analysis in XXXX .

answer: @entity0


abstract: BACKGROUND: @entity4 are frequently seen in @entity0 undergoing cesarean section (CS) under regional anesthesia. We aimed to compare the antiemetic efficacy of @entity5 and @entity3 combination with that of the use of each agent alone to decrease the incidence of postdelivery intra- and post-operative @entity4 during CS under spinal anesthesia. MATERIALS AND METHODS: A randomized, prospective, double-blind study was performed on 90 @entity0 undergoing planned CS under spinal anesthesia. The @entity0 received 4 mg @entity5 in Group O, 8 mg @entity3 in Group D, and 4 mg @entity5 +8 mg @entity3 in Group OD intravenously within 1-2 min after the umbilical cord was clamped. Frequency of postdelivery intra- and post-operative @entity4 episodes was recorded. RESULTS: A total of 90 eligible @entity0 were included in the study. There were 30 @entity0 in Group O, 30 @entity0 in Group D, and 30 @entity0 in Group OD. Intraoperative @entity1 in Group D was more than the other two groups. @entity4 in group OD was lesser than the other two groups. Intraoperative @entity2 in Group OD was lesser than the other two groups. There was no statistically significant difference among the @entity4 (P > 0.05). CONCLUSION: Combined use of @entity3 and @entity5 for the same indication seems to increase the antiemetic efficacy.

title: Comparing the effect of intravenous XXXX , intravenous @entity5 , and their combination on @entity4 in cesarean section with spinal anesthesia.

answer: @entity3


abstract: BACKGROUND: @entity4 are frequently seen in @entity0 undergoing cesarean section (CS) under regional anesthesia. We aimed to compare the antiemetic efficacy of @entity5 and @entity3 combination with that of the use of each agent alone to decrease the incidence of postdelivery intra- and post-operative @entity4 during CS under spinal anesthesia. MATERIALS AND METHODS: A randomized, prospective, double-blind study was performed on 90 @entity0 undergoing planned CS under spinal anesthesia. The @entity0 received 4 mg @entity5 in Group O, 8 mg @entity3 in Group D, and 4 mg @entity5 +8 mg @entity3 in Group OD intravenously within 1-2 min after the umbilical cord was clamped. Frequency of postdelivery intra- and post-operative @entity4 episodes was recorded. RESULTS: A total of 90 eligible @entity0 were included in the study. There were 30 @entity0 in Group O, 30 @entity0 in Group D, and 30 @entity0 in Group OD. Intraoperative @entity1 in Group D was more than the other two groups. @entity4 in group OD was lesser than the other two groups. Intraoperative @entity2 in Group OD was lesser than the other two groups. There was no statistically significant difference among the @entity4 (P > 0.05). CONCLUSION: Combined use of @entity3 and @entity5 for the same indication seems to increase the antiemetic efficacy.

title: Comparing the effect of intravenous @entity3 , intravenous @entity5 , and their combination on XXXX in cesarean section with spinal anesthesia.

answer: @entity4


abstract: BACKGROUND: @entity4 are frequently seen in @entity0 undergoing cesarean section (CS) under regional anesthesia. We aimed to compare the antiemetic efficacy of @entity5 and @entity3 combination with that of the use of each agent alone to decrease the incidence of postdelivery intra- and post-operative @entity4 during CS under spinal anesthesia. MATERIALS AND METHODS: A randomized, prospective, double-blind study was performed on 90 @entity0 undergoing planned CS under spinal anesthesia. The @entity0 received 4 mg @entity5 in Group O, 8 mg @entity3 in Group D, and 4 mg @entity5 +8 mg @entity3 in Group OD intravenously within 1-2 min after the umbilical cord was clamped. Frequency of postdelivery intra- and post-operative @entity4 episodes was recorded. RESULTS: A total of 90 eligible @entity0 were included in the study. There were 30 @entity0 in Group O, 30 @entity0 in Group D, and 30 @entity0 in Group OD. Intraoperative @entity1 in Group D was more than the other two groups. @entity4 in group OD was lesser than the other two groups. Intraoperative @entity2 in Group OD was lesser than the other two groups. There was no statistically significant difference among the @entity4 (P > 0.05). CONCLUSION: Combined use of @entity3 and @entity5 for the same indication seems to increase the antiemetic efficacy.

title: Comparing the effect of intravenous @entity3 , intravenous XXXX , and their combination on @entity4 in cesarean section with spinal anesthesia.

answer: @entity5


abstract: UNASSIGNED: @entity1 is a common disease. However, its causes and morphological features of diseased cartilage surfaces are not well understood. The purposes of this research were (a) to develop quantitative surface characterization techniques to study @entity0 cartilages at a micron and submicron scale and (b) to investigate distinctive changes in the surface morphologies and biomechanical properties of the cartilages in different @entity1 grades. Diseased cartilage samples collected from @entity1 @entity0 were prepared for image acquisition using two different techniques, that is, laser scanning microscopy at a micrometer scale and atomic force microscopy at a nanometer scale. Three-dimensional, digital images of @entity0 cartilages were processed and analyzed quantitatively. This study has demonstrated that high-quality three-dimensional images of @entity0 cartilage surfaces could be obtained in a hydrated condition using laser scanning microscopy and atomic force microscopy. Based on the numerical data extracted from improved image quality and quantity, it has been found that @entity1 evolution can be identified by specific surface features at the micrometer scale, and these features are amplitude and functional property related. At the submicron level, the spatial features of the surfaces were revealed to differ between early and advanced @entity1 grades. The effective indentation moduli of @entity0 cartilages effectively revealed the cartilage deterioration. The imaging acquisition and numerical analysis methods established allow quantitative studies of distinctive changes in cartilage surface characteristics and better understanding of the cartilage degradation process.

title: Investigations of micron and submicron wear features of diseased XXXX cartilage surfaces.

answer: @entity0


abstract: BACKGROUND AND PURPOSE: MR imaging findings of @entity4 , @entity4 wall enhancement, perianeurysmal @entity1 , and @entity6 following deployment of flow-diverting stents may be relevant to those @entity0 who subsequently experience procedure-related @entity7 . We sought to document the routine early postoperative MR imaging findings following flow-diverting stent insertion. MATERIALS AND METHODS: @entity0 requiring flow-diverting stent placement for treatment or retreatment of @entity3 were prospectively included in the study during a 26-month period. Early postprocedural MR imaging studies were obtained and compared with preoperative imaging. @entity0 clinical outcome data were also collected. RESULTS: There were 34 stent-placement procedures during the study period. @entity4 and mild new perianeurysmal @entity1 were present in 50% and 14%, respectively. Any @entity2 was present in 57% of cases. New or possibly new foci of susceptibility effect were found ipsilateral to the stent and not associated with diffusion restriction in 66% of cases. There were 2 cases (6%) of @entity5 and 2 major clinical complications (6%) causing permanent morbidity. CONCLUSIONS: Asymptomatic @entity4 mural enhancement is frequently seen following flow-diverting stent placement and should not necessarily be interpreted as a sign of impending @entity8 . This finding often persists despite complete @entity4 . New small brain parenchymal susceptibility foci following stent placement have not previously been reported, to our knowledge, but were common in our series.

title: Prospective Study of Early MRI Appearances following Flow-Diverting Stent Placement for XXXX .

answer: @entity3


abstract: OBJECTIVE: @entity8 ( @entity8 ) have often been linked to psychopathology. The aim of the current study was to compare prevalence rates of @entity1 among individuals with @entity10 ( @entity10 ), @entity3 ( @entity3 ), and @entity7 ( @entity7 ). METHODS: This study was conducted in 94,516 @entity0 (mean [standard deviation] age = 44.6 [12.5] years, 58.7% @entity0 ) of the general-population cohort LifeLines. @entity8 were assessed by self-reports. @entity6 (i.e., major @entity4 and dysthymia) and @entity2 (i.e., generalized @entity2 , @entity5 , @entity9 with/without @entity11 , and @entity11 ) were assessed by means of the Mini International Neuropsychiatric Interview. Risks on @entity1 were compared for individuals with @entity10 , @entity3 , and @entity7 by using logistic regression analyses adjusted for age and sex. RESULTS: Prevalence rates of @entity10 , @entity3 , and @entity7 were 1.3%, 3.0%, and 9.7%, respectively. Individuals with @entity10 , @entity3 , and @entity7 had significantly more mood (odds ratios [ORs] = 1.72-5.42) and @entity2 (ORs = 1.52-3.96) than did individuals without @entity8 , but prevalence rates were low (1.6%-28.6%). Individuals with @entity10 more often had mood (ORs = 2.00-4.08) and @entity2 (ORs = 1.63-2.32) than did individuals with @entity3 and @entity7 . @entity4 was more common in @entity3 than in @entity7 (OR = 1.58, 95% confidence interval = 1.24-2.01), whereas these groups did not differ on dysthymia or @entity2 . CONCLUSIONS: Mood and @entity2 are more prevalent in individuals with @entity8 , and particularly @entity10 , than in individuals without @entity8 . However, most individuals with @entity8 do not have mood or @entity2 .

title: Mood and @entity2 in @entity10 , XXXX , and Irritable Bowel Syndrome: Results From the LifeLines Cohort Study.

answer: @entity3


abstract: OBJECTIVE: @entity8 ( @entity8 ) have often been linked to psychopathology. The aim of the current study was to compare prevalence rates of @entity1 among individuals with @entity10 ( @entity10 ), @entity3 ( @entity3 ), and @entity7 ( @entity7 ). METHODS: This study was conducted in 94,516 @entity0 (mean [standard deviation] age = 44.6 [12.5] years, 58.7% @entity0 ) of the general-population cohort LifeLines. @entity8 were assessed by self-reports. @entity6 (i.e., major @entity4 and dysthymia) and @entity2 (i.e., generalized @entity2 , @entity5 , @entity9 with/without @entity11 , and @entity11 ) were assessed by means of the Mini International Neuropsychiatric Interview. Risks on @entity1 were compared for individuals with @entity10 , @entity3 , and @entity7 by using logistic regression analyses adjusted for age and sex. RESULTS: Prevalence rates of @entity10 , @entity3 , and @entity7 were 1.3%, 3.0%, and 9.7%, respectively. Individuals with @entity10 , @entity3 , and @entity7 had significantly more mood (odds ratios [ORs] = 1.72-5.42) and @entity2 (ORs = 1.52-3.96) than did individuals without @entity8 , but prevalence rates were low (1.6%-28.6%). Individuals with @entity10 more often had mood (ORs = 2.00-4.08) and @entity2 (ORs = 1.63-2.32) than did individuals with @entity3 and @entity7 . @entity4 was more common in @entity3 than in @entity7 (OR = 1.58, 95% confidence interval = 1.24-2.01), whereas these groups did not differ on dysthymia or @entity2 . CONCLUSIONS: Mood and @entity2 are more prevalent in individuals with @entity8 , and particularly @entity10 , than in individuals without @entity8 . However, most individuals with @entity8 do not have mood or @entity2 .

title: Mood and @entity2 in XXXX , @entity3 , and Irritable Bowel Syndrome: Results From the LifeLines Cohort Study.

answer: @entity10


abstract: OBJECTIVE: @entity8 ( @entity8 ) have often been linked to psychopathology. The aim of the current study was to compare prevalence rates of @entity1 among individuals with @entity10 ( @entity10 ), @entity3 ( @entity3 ), and @entity7 ( @entity7 ). METHODS: This study was conducted in 94,516 @entity0 (mean [standard deviation] age = 44.6 [12.5] years, 58.7% @entity0 ) of the general-population cohort LifeLines. @entity8 were assessed by self-reports. @entity6 (i.e., major @entity4 and dysthymia) and @entity2 (i.e., generalized @entity2 , @entity5 , @entity9 with/without @entity11 , and @entity11 ) were assessed by means of the Mini International Neuropsychiatric Interview. Risks on @entity1 were compared for individuals with @entity10 , @entity3 , and @entity7 by using logistic regression analyses adjusted for age and sex. RESULTS: Prevalence rates of @entity10 , @entity3 , and @entity7 were 1.3%, 3.0%, and 9.7%, respectively. Individuals with @entity10 , @entity3 , and @entity7 had significantly more mood (odds ratios [ORs] = 1.72-5.42) and @entity2 (ORs = 1.52-3.96) than did individuals without @entity8 , but prevalence rates were low (1.6%-28.6%). Individuals with @entity10 more often had mood (ORs = 2.00-4.08) and @entity2 (ORs = 1.63-2.32) than did individuals with @entity3 and @entity7 . @entity4 was more common in @entity3 than in @entity7 (OR = 1.58, 95% confidence interval = 1.24-2.01), whereas these groups did not differ on dysthymia or @entity2 . CONCLUSIONS: Mood and @entity2 are more prevalent in individuals with @entity8 , and particularly @entity10 , than in individuals without @entity8 . However, most individuals with @entity8 do not have mood or @entity2 .

title: Mood and XXXX in @entity10 , @entity3 , and Irritable Bowel Syndrome: Results From the LifeLines Cohort Study.

answer: @entity2


abstract: Members of the heterochromatin protein 1 family ( @entity5 , b and y) are mostly associated with heterochromatin and play important roles in gene regulation and DNA damage response. Altered expression of individual @entity5 subtype has profound impacts on cell proliferation and tumorigenesis. We analyzed the expression profile of @entity5 family by data mining using a published microarray data set coupled with retrospective immunohistochemistry analyses of archived @entity0 biospecimens. We found that the @entity1 group overexpressing @entity6 mRNA is associated with poorly differentiated @entity0 and with a significantly lower survival rate. Immunohistochemical staining against @entity5 , @entity6 and HP1y shows that respective @entity5 expression level is frequently altered in @entity0 . 57.4-60.1% of samples examined showed high @entity6 expression and 39.9-42.6 % of examined @entity2 showed no or low expression of each @entity5 subtype. Interestingly, comparative analysis on @entity5 expression profile and @entity0 markers revealed a positive correlation between the respective expression level of all three @entity5 subtypes and Ki-67, a cell proliferation and well-known @entity0 marker. To explore the effect of individual @entity5 on @entity4 inhibitor therapy for @entity0 , MCF7 @entity0 cells and individually @entity5 -depleted MCF7 cells were treated with @entity4 inhibitor @entity7 with or without @entity3 . Notably, @entity6 -knockdown cells are hypersensitive to the @entity4 inhibitor @entity7 alone and its combination with @entity3 . In summary, while increased @entity6 expression is associated with the poor prognosis in @entity0 , compromised @entity6 abundance may serve as a useful predictive marker for chemotherapy, including @entity4 inhibitors against @entity0 .

title: @entity6 is a biomarker for @entity0 prognosis and XXXX inhibitor therapy.

answer: @entity4


abstract: Members of the heterochromatin protein 1 family ( @entity5 , b and y) are mostly associated with heterochromatin and play important roles in gene regulation and DNA damage response. Altered expression of individual @entity5 subtype has profound impacts on cell proliferation and tumorigenesis. We analyzed the expression profile of @entity5 family by data mining using a published microarray data set coupled with retrospective immunohistochemistry analyses of archived @entity0 biospecimens. We found that the @entity1 group overexpressing @entity6 mRNA is associated with poorly differentiated @entity0 and with a significantly lower survival rate. Immunohistochemical staining against @entity5 , @entity6 and HP1y shows that respective @entity5 expression level is frequently altered in @entity0 . 57.4-60.1% of samples examined showed high @entity6 expression and 39.9-42.6 % of examined @entity2 showed no or low expression of each @entity5 subtype. Interestingly, comparative analysis on @entity5 expression profile and @entity0 markers revealed a positive correlation between the respective expression level of all three @entity5 subtypes and Ki-67, a cell proliferation and well-known @entity0 marker. To explore the effect of individual @entity5 on @entity4 inhibitor therapy for @entity0 , MCF7 @entity0 cells and individually @entity5 -depleted MCF7 cells were treated with @entity4 inhibitor @entity7 with or without @entity3 . Notably, @entity6 -knockdown cells are hypersensitive to the @entity4 inhibitor @entity7 alone and its combination with @entity3 . In summary, while increased @entity6 expression is associated with the poor prognosis in @entity0 , compromised @entity6 abundance may serve as a useful predictive marker for chemotherapy, including @entity4 inhibitors against @entity0 .

title: @entity6 is a biomarker for XXXX prognosis and @entity4 inhibitor therapy.

answer: @entity0


abstract: Members of the heterochromatin protein 1 family ( @entity5 , b and y) are mostly associated with heterochromatin and play important roles in gene regulation and DNA damage response. Altered expression of individual @entity5 subtype has profound impacts on cell proliferation and tumorigenesis. We analyzed the expression profile of @entity5 family by data mining using a published microarray data set coupled with retrospective immunohistochemistry analyses of archived @entity0 biospecimens. We found that the @entity1 group overexpressing @entity6 mRNA is associated with poorly differentiated @entity0 and with a significantly lower survival rate. Immunohistochemical staining against @entity5 , @entity6 and HP1y shows that respective @entity5 expression level is frequently altered in @entity0 . 57.4-60.1% of samples examined showed high @entity6 expression and 39.9-42.6 % of examined @entity2 showed no or low expression of each @entity5 subtype. Interestingly, comparative analysis on @entity5 expression profile and @entity0 markers revealed a positive correlation between the respective expression level of all three @entity5 subtypes and Ki-67, a cell proliferation and well-known @entity0 marker. To explore the effect of individual @entity5 on @entity4 inhibitor therapy for @entity0 , MCF7 @entity0 cells and individually @entity5 -depleted MCF7 cells were treated with @entity4 inhibitor @entity7 with or without @entity3 . Notably, @entity6 -knockdown cells are hypersensitive to the @entity4 inhibitor @entity7 alone and its combination with @entity3 . In summary, while increased @entity6 expression is associated with the poor prognosis in @entity0 , compromised @entity6 abundance may serve as a useful predictive marker for chemotherapy, including @entity4 inhibitors against @entity0 .

title: XXXX is a biomarker for @entity0 prognosis and @entity4 inhibitor therapy.

answer: @entity6


abstract: PURPOSE: To monitor @entity2 ( @entity2 ) @entity1 progression during antiangiogenic therapy of neovascular @entity3 ( @entity3 ) over 2 years using polarization-sensitive optical coherence tomography (OCT). DESIGN: Prospective interventional case series. METHODS: setting: Clinical practice. STUDY POPULATION: Thirty @entity0 (31 eyes) with treatment-na  ve neovascular @entity3 . OBSERVATION PROCEDURES: Standard intravitreal therapy (0.5  mg ranibizumab) was administered monthly during the first year and pro re nata (PRN; as-needed) during the second year. Spectral-domain (SD) OCT and polarization-sensitive OCT (selectively imaging the @entity2 ) examinations were performed at baseline and at 1, 3, 6, 12, and 24  months using a standardized protocol. @entity2 -related changes were evaluated using a semi-automated polarization-sensitive OCT segmentation algorithm and correlated with SD OCT and fundus autofluorescence (FAF) findings. MAIN OUTCOME MEASURES: @entity2 response, @entity5 ( @entity5 ) progression. RESULTS: Atrophic @entity2 changes included @entity2 thinning, @entity2 porosity, focal @entity4 , and development of @entity5 . Early @entity2 loss (ie, @entity2 porosity, focal @entity1 ) increased progressively during initial monthly treatment and remained stable during subsequent PRN-based therapy. @entity5 developed in 61% of eyes at month 24. Mean @entity5 area increased from 0.77  mm(2) at 12  months to 1.10  mm(2) (standard deviation  = 1.09  mm(2)) at 24  months. Reactive accumulation of @entity2 -related material at the lesion borders increased until month 3 and subsequently decreased. CONCLUSIONS: Progressive @entity4 and @entity5 developed in the majority of eyes. @entity2 migration signifies certain @entity2 plasticity. Polarization-sensitive OCT specifically images @entity2 -related changes in neovascular @entity3 , contrary to conventional imaging methods. Polarization-sensitive OCT allows for precisely monitoring the sequence of @entity2 -related morphologic changes.

title: Progression of Retinal Pigment Epithelial Atrophy in Antiangiogenic Therapy of Neovascular Age-Related XXXX .

answer: @entity3


abstract: OBJECTIVE: Sutureless prostheses for surgical @entity3 ( @entity3 ) are usually used in degenerative calcified @entity2 . Less is known on the application of sutureless prostheses for pure @entity1 . METHODS: Between 2011 and 2014, 442 @entity0 were operated on with the Perceval aortic sutureless valve implant. We identified 11 @entity0 (10 female, mean age 70.5) who underwent sutureless @entity3 for pure @entity1 (off-label use). Three @entity0 had a left ventricle ejection fraction of 30% or less. Mean logistic EuroSCORE was 15.2 (range 2.2-45.2). In five @entity0 associated mitral procedures (three [60%] repair and two [40%] replacement) were performed. Four procedures were performed through a minimally invasive approach (three right minithoracotomies and one partial sternotomy). RESULTS: Mean cardiopulmonary bypass time was 130.2   min and aortic cross clamp time was 82.2   min. Mean implanted prosthesis size was 24.5        1.3 (median 25) mm (insignificant correlation with preoperative aortic valve annulus measurement by transthoracic echocardiography: 21.6        1.5 [median 21] mm, Pearson's r   =   0.373, p   =   0.259). One @entity0 died on 24th day after @entity3 associated with aortic arch replacement and hypothermic @entity4 (10 years after correction for @entity5 ). No residual para- or intravalvular leakage was present on discharge and 12-month follow-up. No migration of the prosthesis occurred. CONCLUSION: Sutureless @entity3 is an option in selected @entity0 with @entity1 . Preoperative aortic annulus measurement by echocardiography has poor predictive value for estimation of prosthetic valve size.

title: Sutureless Aortic Valve Replacement for XXXX .

answer: @entity1


abstract: UNASSIGNED: One option for achieving global polio eradication is to replace the oral @entity3 vaccine (OPV), which has the risk of reversion to wild-type virulence, with the inactivated @entity3 vaccine (IPV) vaccine. Adjuvants and alternate routes of immunization are promising options that may reduce antigen dose in IPV vaccinations, potentially allowing dose sparing and cost savings. Use of adjuvants and alternate routes of immunization could also help promote @entity1 , potentially mimicking the protection against intestinal virus shedding seen with OPV. In the current study, we examined the impact of combining the novel adjuvant dmLT with trivalent IPV for dose sparing, induction of @entity1 and increasing longevity of @entity2 ( @entity2 ) responses in a @entity0 model following either intradermal (ID) or intramuscular (IM) delivery. We found that non-adjuvanted ID delivery was not superior to IM delivery for fractional dose sparing, but was associated with development of @entity1 . Vaccination with IPV+dmLT promoted serum anti- @entity2 neutralizing antibodies with fractional IPV doses by either IM or ID delivery, achieving at least five-fold dose sparing above non-adjuvanted fractional doses. These responses were most noticeable with the @entity4 component of the trivalent vaccine. dmLT also promoted germinal center formation and longevity of serum anti- @entity2 neutralizing titers. Lastly, dmLT enhanced @entity1 , as defined by fecal and intestinal anti- @entity2 IgA secretion, when included in IPV immunization by ID or IM delivery. These studies demonstrate that dmLT is an effective adjuvant for either IM or ID delivery of IPV. Inclusion of dmLT in IPV immunizations allows antigen dose sparing and enhances @entity1 and longevity of anti- @entity2 responses.

title: The novel adjuvant dmLT promotes dose sparing, XXXX and longevity of antibody responses to the inactivated polio vaccine in a @entity0 model.

answer: @entity1


abstract: UNASSIGNED: One option for achieving global polio eradication is to replace the oral @entity3 vaccine (OPV), which has the risk of reversion to wild-type virulence, with the inactivated @entity3 vaccine (IPV) vaccine. Adjuvants and alternate routes of immunization are promising options that may reduce antigen dose in IPV vaccinations, potentially allowing dose sparing and cost savings. Use of adjuvants and alternate routes of immunization could also help promote @entity1 , potentially mimicking the protection against intestinal virus shedding seen with OPV. In the current study, we examined the impact of combining the novel adjuvant dmLT with trivalent IPV for dose sparing, induction of @entity1 and increasing longevity of @entity2 ( @entity2 ) responses in a @entity0 model following either intradermal (ID) or intramuscular (IM) delivery. We found that non-adjuvanted ID delivery was not superior to IM delivery for fractional dose sparing, but was associated with development of @entity1 . Vaccination with IPV+dmLT promoted serum anti- @entity2 neutralizing antibodies with fractional IPV doses by either IM or ID delivery, achieving at least five-fold dose sparing above non-adjuvanted fractional doses. These responses were most noticeable with the @entity4 component of the trivalent vaccine. dmLT also promoted germinal center formation and longevity of serum anti- @entity2 neutralizing titers. Lastly, dmLT enhanced @entity1 , as defined by fecal and intestinal anti- @entity2 IgA secretion, when included in IPV immunization by ID or IM delivery. These studies demonstrate that dmLT is an effective adjuvant for either IM or ID delivery of IPV. Inclusion of dmLT in IPV immunizations allows antigen dose sparing and enhances @entity1 and longevity of anti- @entity2 responses.

title: The novel adjuvant dmLT promotes dose sparing, @entity1 and longevity of antibody responses to the inactivated polio vaccine in a XXXX model.

answer: @entity0


abstract: UNASSIGNED: Botulinum toxin A (BTX-A) blocks the release of @entity4 vesicles into the synaptic space, and has been clinically used for aesthetic indications, @entity7 and @entity6 . Several studies have demonstrated that BTX-A enhanced the blood flow and improved @entity2 in animal models. Our objective was to assess the effects of BTX-A on cutaneous @entity2 -reperfusion (I/R) injuries, mimicking @entity9 . The administration of BTX-A in I/R areas significantly inhibited the formation of @entity9 -like @entity5 in cutaneous I/R injury @entity0 model. The number of @entity8 (+) vessels and aSMA(+) pericytes or myofibroblasts in wounds were significantly increased in the I/R @entity0 treated with BTX-A. The @entity3 area and the number of oxidative stress-associated DNA-damaged cells and apoptotic cells in the I/R sites were reduced by BTX-A administration. In an in vitro assay, BTX-A significantly prevented the oxidant-induced intracellular accumulation of reactive @entity1 species (ROS) in vascular endothelial cells. Furthermore, the administration of BTX-A completely suppressed the @entity5 formation in an intermittent short-time cutaneous I/R injury model. These results suggest that BTX-A might have protective effects against @entity5 formation after cutaneous I/R injury by enhancing angiogenesis and inhibiting @entity3 -induced cellular damage. Exogenous application of BTX-A might have therapeutic potential for cutaneous I/R injuries.

title: Protective effect of botulinum toxin A after cutaneous XXXX -reperfusion injury.

answer: @entity2


abstract: UNASSIGNED: The mortality rate due to @entity3 of @entity8 and @entity5 is approximately 90%. Acute @entity9 can be fatal prior to hospitalization and has proven difficult to diagnose correctly or predict. The in-hospital mortality rate of ruptured @entity5 ranges from 53 to 66%. Emergency surgical and endovascular treatments are the only options for @entity9 and @entity5 . No method of systematic early detection or inspection of vessel injury is available at the prevention stage. Regardless of the improvement in many imaging modalities, aortic diameter has remained a major criterion for recommending surgery in diagnosed @entity0 . Previous reports have suggested a relationship between vulnerable plaque and @entity6 . Non-obstructive angioscopy is a new method for evaluating intimal injury over the whole aorta. It has been used to identify many advanced @entity6 plaques that were missed on traditional imaging modalities before @entity4 formation. Non-obstructive angioscopy has shown that @entity6 of the aorta begins before that of the coronary artery, which had been noted on autopsy "in vivo". Strong or repetitive @entity2 might cause sudden aortic disruption. @entity10 is also a risk factor of @entity1 and perivascular @entity7 . Detecting aortic vulnerable @entity6 plaque on non-obstructive angioscopy may not only clarify the pathogenesis of acute @entity9 but also play a role in the pre-emptive medicine.

title: Early Detection of Vulnerable Atherosclerotic Plaque for Risk Reduction of Acute XXXX and Thromboemboli and Atheroemboli Using Non-Obstructive Angioscopy.

answer: @entity9


abstract: UNASSIGNED: Endovascular treatment of @entity2 is challenging and often limited by its unique anatomic, hemodynamic and biomechanical constraints. Despite technical improvement, percutaneous transluminal angioplasty alone is not adequate to provide satisfactory long-term patency. Several randomized controlled trials have shown that primary @entity4 stenting can provide a better short-term radiological patency in intermediate lesion, but the results were often limited by intrinsic stent complications, particularly in-stent @entity1 . Solutions to long lesions have been more elusive. To date, many novel technologies have been developed with a goal of improving stent design for this specific environment. Interwoven stents are made to provide a higher radial strength and kink resistance. Covered stents are designed to prevent the ingrowth of @entity3 , which is the main cause of @entity1 in bare metal stent. Drug-eluting stents have shown improved patency in clinical trials. Bioabsorbable stents, combining biological agents and mechanical scaffold, provide temporary vascular support while reducing implant-related @entity0 in the long term. New developments in balloon angioplasty, such as drug elution, provide a challenge to stenting in this arena. Although these technologies look promising, a uniform reporting system and large-scale comparative studies with longer follow-up are needed to evaluate their clinical effectiveness in the future.

title: Primary Stenting in XXXX   - What Is the Appropriate Role?

answer: @entity2


abstract: BACKGROUND/AIMS: The @entity0 ( @entity0 , FA/FA) @entity1 is a genetic model of @entity2 2 @entity0 , characterized by insulin resistance with progressive @entity3 . We have previously demonstrated @entity5 and oxidative stress in the heart, kidneys and pancreas of @entity0 @entity1 . However, the precise molecular mechanism of disease progression is not clear. Our aim in the present study was to investigate oxidative stress and @entity5 in the liver and brain of @entity0 @entity1 . METHODS: In this study, we have measured mitochondrial oxidative stress, bioenergetics and redox homeostasis in the liver and brain of @entity0 @entity1 . RESULTS: Our results showed increased reactive oxygen species (ROS) production in the @entity0 @entity1 brain compared to the liver, while nitric oxide (NO) production was markedly increased both in the brain and liver. High levels of lipid and protein peroxidation were also observed in these tissues. Glutathione metabolism and mitochondrial respiratory functions were adversely affected in @entity0 @entity1 when compared to Zucker lean (ZL, +/FA) control @entity1 . Reduced ATP synthesis was also observed in the liver and brain of @entity0 @entity1 . Western blot analysis confirmed altered expression of cytochrome P450 2E1, @entity4 , p-JNK, and IkB-a confirming an increase in oxidative and metabolic stress in @entity0 @entity1 tissues. CONCLUSIONS: Our data shows that, like other tissues, @entity0 @entity1 liver and brain develop complications associated with redox homeostasis and @entity5 . These results, thus, might have implications in understanding the etiology and pathophysiology of diabesity which in turn, would help in managing the disease associated complications.    2015 S. Karger AG, Basel.

title: Increased Oxidative Stress and Mitochondrial Dysfunction in Zucker Diabetic XXXX Liver and Brain.

answer: @entity1


abstract: BACKGROUND/PURPOSE: Gastric @entity3 ( @entity3 ) have a highly variable clinical course, and recurrent disease sometimes develops despite curative surgery. This study was undertaken to investigate the surgical role in treating @entity4 and evaluate the clinicopathological features of a large series of @entity0 who underwent curative resection for @entity4 to clarify which features were independent prognostic factors. METHODS: The clinicopathological data of 406 @entity0 with @entity4 who underwent curative resection at 4 university hospitals in Daegu, South Korea, from March 1998 to March 2012 were reviewed. All cases were confirmed as @entity4 by immunohistochemical staining, in which @entity6 or @entity5 was positive. Clinical follow-up was performed periodically, and disease-free survival rates were retrospectively investigated using the medical records. RESULTS: The mean follow-up period was 42.9 months (range: 2-166). There were 11 recurrent @entity0 (2.7%). Due to the small number of recurrences, age, sex and location were controlled using propensity score matching before performing any statistical analysis. @entity1 size, mitotic count, NIH classification, and cellularity were judged to be independent prognostic factors for recurrence by univariate analysis. In a multivariate analysis, @entity1 size and mitotic count were significantly and independently related to recurrence, and @entity1 size was determined to be the most important prognostic factor for recurrence after curative resection (hazard ratio: 1.204; p < 0.01). CONCLUSIONS: The results of this multicenter study demonstrate that disease-free survival rates are good. @entity1 size was disclosed as the most important factor for recurrence in @entity2 @entity0 who underwent radical resection.    2015 S. Karger AG, Basel.

title: Prognostic Factors of @entity0 with XXXX after Curative Resection: A Retrospective Analysis of 406 Consecutive Cases in a Multicenter Study.

answer: @entity4


abstract: BACKGROUND/PURPOSE: Gastric @entity3 ( @entity3 ) have a highly variable clinical course, and recurrent disease sometimes develops despite curative surgery. This study was undertaken to investigate the surgical role in treating @entity4 and evaluate the clinicopathological features of a large series of @entity0 who underwent curative resection for @entity4 to clarify which features were independent prognostic factors. METHODS: The clinicopathological data of 406 @entity0 with @entity4 who underwent curative resection at 4 university hospitals in Daegu, South Korea, from March 1998 to March 2012 were reviewed. All cases were confirmed as @entity4 by immunohistochemical staining, in which @entity6 or @entity5 was positive. Clinical follow-up was performed periodically, and disease-free survival rates were retrospectively investigated using the medical records. RESULTS: The mean follow-up period was 42.9 months (range: 2-166). There were 11 recurrent @entity0 (2.7%). Due to the small number of recurrences, age, sex and location were controlled using propensity score matching before performing any statistical analysis. @entity1 size, mitotic count, NIH classification, and cellularity were judged to be independent prognostic factors for recurrence by univariate analysis. In a multivariate analysis, @entity1 size and mitotic count were significantly and independently related to recurrence, and @entity1 size was determined to be the most important prognostic factor for recurrence after curative resection (hazard ratio: 1.204; p < 0.01). CONCLUSIONS: The results of this multicenter study demonstrate that disease-free survival rates are good. @entity1 size was disclosed as the most important factor for recurrence in @entity2 @entity0 who underwent radical resection.    2015 S. Karger AG, Basel.

title: Prognostic Factors of XXXX with @entity4 after Curative Resection: A Retrospective Analysis of 406 Consecutive Cases in a Multicenter Study.

answer: @entity0


abstract: UNASSIGNED: @entity4 is a disease whose clinical spectrum depends on the cytokine patterns produced during the early stages of the immune response. The main objective of this study was to describe the activation pattern of cellular transcription factors and to correlate these factors with the clinical forms of @entity4 . Skin samples were obtained from 16 @entity0 with the tuberculoid (TT) form and 14 with the lepromatous (LL) form. The histologic sections were immunostained with anti- @entity5 and anti- @entity2 monoclonal antibodies for investigation of @entity2 , anti-NFkB @entity11 for the study of NFkB, and anti- @entity6 , @entity9 , @entity7 , and @entity10 for investigation of the JAK/STAT pathway. Cells expressing @entity9 were more frequent in the TT form than in LL lesions (P = .0096), in agreement with the protective immunity provided by @entity1 . @entity10 was also more highly expressed in the TT form than in the LL form (P = .0098). This transcription factor is essential for the development of a @entity3 response because it is associated with interleukin-12. NFkB ( @entity11 ) and @entity10 expression in the TT form showed a strong and significant correlation (r = 0.7556 and P = .0007). A moderate and significant correlation was observed between @entity6 and @entity10 in the TT form (r = 0.6637 and P = .0051), with these factors responding to interleukin-12 in @entity3 profiles. The results suggest that @entity9 , @entity6 , and NFkB, together with @entity10 , contribute to the development of cell-mediated immunity, which is able to contain the proliferation of @entity8 .

title: Immunohistochemical analysis of the expression of cellular transcription NFkB ( @entity11 ), @entity2 ( @entity5 and @entity2 ), and JAK/STAT in XXXX .

answer: @entity4


abstract: UNASSIGNED: @entity4 is a disease whose clinical spectrum depends on the cytokine patterns produced during the early stages of the immune response. The main objective of this study was to describe the activation pattern of cellular transcription factors and to correlate these factors with the clinical forms of @entity4 . Skin samples were obtained from 16 @entity0 with the tuberculoid (TT) form and 14 with the lepromatous (LL) form. The histologic sections were immunostained with anti- @entity5 and anti- @entity2 monoclonal antibodies for investigation of @entity2 , anti-NFkB @entity11 for the study of NFkB, and anti- @entity6 , @entity9 , @entity7 , and @entity10 for investigation of the JAK/STAT pathway. Cells expressing @entity9 were more frequent in the TT form than in LL lesions (P = .0096), in agreement with the protective immunity provided by @entity1 . @entity10 was also more highly expressed in the TT form than in the LL form (P = .0098). This transcription factor is essential for the development of a @entity3 response because it is associated with interleukin-12. NFkB ( @entity11 ) and @entity10 expression in the TT form showed a strong and significant correlation (r = 0.7556 and P = .0007). A moderate and significant correlation was observed between @entity6 and @entity10 in the TT form (r = 0.6637 and P = .0051), with these factors responding to interleukin-12 in @entity3 profiles. The results suggest that @entity9 , @entity6 , and NFkB, together with @entity10 , contribute to the development of cell-mediated immunity, which is able to contain the proliferation of @entity8 .

title: Immunohistochemical analysis of the expression of cellular transcription NFkB ( @entity11 ), XXXX ( @entity5 and @entity2 ), and JAK/STAT in @entity4 .

answer: @entity2


abstract: UNASSIGNED: @entity4 is a disease whose clinical spectrum depends on the cytokine patterns produced during the early stages of the immune response. The main objective of this study was to describe the activation pattern of cellular transcription factors and to correlate these factors with the clinical forms of @entity4 . Skin samples were obtained from 16 @entity0 with the tuberculoid (TT) form and 14 with the lepromatous (LL) form. The histologic sections were immunostained with anti- @entity5 and anti- @entity2 monoclonal antibodies for investigation of @entity2 , anti-NFkB @entity11 for the study of NFkB, and anti- @entity6 , @entity9 , @entity7 , and @entity10 for investigation of the JAK/STAT pathway. Cells expressing @entity9 were more frequent in the TT form than in LL lesions (P = .0096), in agreement with the protective immunity provided by @entity1 . @entity10 was also more highly expressed in the TT form than in the LL form (P = .0098). This transcription factor is essential for the development of a @entity3 response because it is associated with interleukin-12. NFkB ( @entity11 ) and @entity10 expression in the TT form showed a strong and significant correlation (r = 0.7556 and P = .0007). A moderate and significant correlation was observed between @entity6 and @entity10 in the TT form (r = 0.6637 and P = .0051), with these factors responding to interleukin-12 in @entity3 profiles. The results suggest that @entity9 , @entity6 , and NFkB, together with @entity10 , contribute to the development of cell-mediated immunity, which is able to contain the proliferation of @entity8 .

title: Immunohistochemical analysis of the expression of cellular transcription NFkB ( @entity11 ), @entity2 ( @entity5 and XXXX ), and JAK/STAT in @entity4 .

answer: @entity2


abstract: UNASSIGNED: @entity4 is a disease whose clinical spectrum depends on the cytokine patterns produced during the early stages of the immune response. The main objective of this study was to describe the activation pattern of cellular transcription factors and to correlate these factors with the clinical forms of @entity4 . Skin samples were obtained from 16 @entity0 with the tuberculoid (TT) form and 14 with the lepromatous (LL) form. The histologic sections were immunostained with anti- @entity5 and anti- @entity2 monoclonal antibodies for investigation of @entity2 , anti-NFkB @entity11 for the study of NFkB, and anti- @entity6 , @entity9 , @entity7 , and @entity10 for investigation of the JAK/STAT pathway. Cells expressing @entity9 were more frequent in the TT form than in LL lesions (P = .0096), in agreement with the protective immunity provided by @entity1 . @entity10 was also more highly expressed in the TT form than in the LL form (P = .0098). This transcription factor is essential for the development of a @entity3 response because it is associated with interleukin-12. NFkB ( @entity11 ) and @entity10 expression in the TT form showed a strong and significant correlation (r = 0.7556 and P = .0007). A moderate and significant correlation was observed between @entity6 and @entity10 in the TT form (r = 0.6637 and P = .0051), with these factors responding to interleukin-12 in @entity3 profiles. The results suggest that @entity9 , @entity6 , and NFkB, together with @entity10 , contribute to the development of cell-mediated immunity, which is able to contain the proliferation of @entity8 .

title: Immunohistochemical analysis of the expression of cellular transcription NFkB ( XXXX ), @entity2 ( @entity5 and @entity2 ), and JAK/STAT in @entity4 .

answer: @entity11


abstract: UNASSIGNED: @entity4 is a disease whose clinical spectrum depends on the cytokine patterns produced during the early stages of the immune response. The main objective of this study was to describe the activation pattern of cellular transcription factors and to correlate these factors with the clinical forms of @entity4 . Skin samples were obtained from 16 @entity0 with the tuberculoid (TT) form and 14 with the lepromatous (LL) form. The histologic sections were immunostained with anti- @entity5 and anti- @entity2 monoclonal antibodies for investigation of @entity2 , anti-NFkB @entity11 for the study of NFkB, and anti- @entity6 , @entity9 , @entity7 , and @entity10 for investigation of the JAK/STAT pathway. Cells expressing @entity9 were more frequent in the TT form than in LL lesions (P = .0096), in agreement with the protective immunity provided by @entity1 . @entity10 was also more highly expressed in the TT form than in the LL form (P = .0098). This transcription factor is essential for the development of a @entity3 response because it is associated with interleukin-12. NFkB ( @entity11 ) and @entity10 expression in the TT form showed a strong and significant correlation (r = 0.7556 and P = .0007). A moderate and significant correlation was observed between @entity6 and @entity10 in the TT form (r = 0.6637 and P = .0051), with these factors responding to interleukin-12 in @entity3 profiles. The results suggest that @entity9 , @entity6 , and NFkB, together with @entity10 , contribute to the development of cell-mediated immunity, which is able to contain the proliferation of @entity8 .

title: Immunohistochemical analysis of the expression of cellular transcription NFkB ( @entity11 ), @entity2 ( XXXX and @entity2 ), and JAK/STAT in @entity4 .

answer: @entity5


abstract: The complement system has been implicated in the physiopathology of @entity5 . Since infection is a major cause of @entity3 in @entity2 @entity0 , we examined daily serum C3 and immunoglobulin levels in all victims of major @entity2 during a 3-month interval. Sixteen @entity0 developed acute systemic @entity4 3-15 days after admission. For all variables the lowest values occurred shortly after hospital admission, during or just after fluid resuscitation. Thereafter, the serum C3 and immunoglobulin concentrations gradually returned to the normal ranges, despite the onset of fulminant systemic @entity4 . Except for IgM, the occurrence of @entity6 during @entity4 did not affect the recovery patterns of the measured variables. In the five @entity0 experiencing @entity6 , serum IgM dropped transiently but resumed its normalization trend after the restoration of adequate perfusion pressure. In the three nonsurvivors there was no reduction in the serum C3 or immunoglobulin levels prior to @entity3 . These data do not support a role for C3 or the immunoglobulins in the pathogenesis of @entity1 . On the contrary, the behavior of these substances during severe @entity4 is more consistent with protective host defense functions.

title: Sequential serum complement (C3) and immunoglobulin levels in shock/ @entity2 @entity0 developing XXXX .

answer: @entity1


abstract: The complement system has been implicated in the physiopathology of @entity5 . Since infection is a major cause of @entity3 in @entity2 @entity0 , we examined daily serum C3 and immunoglobulin levels in all victims of major @entity2 during a 3-month interval. Sixteen @entity0 developed acute systemic @entity4 3-15 days after admission. For all variables the lowest values occurred shortly after hospital admission, during or just after fluid resuscitation. Thereafter, the serum C3 and immunoglobulin concentrations gradually returned to the normal ranges, despite the onset of fulminant systemic @entity4 . Except for IgM, the occurrence of @entity6 during @entity4 did not affect the recovery patterns of the measured variables. In the five @entity0 experiencing @entity6 , serum IgM dropped transiently but resumed its normalization trend after the restoration of adequate perfusion pressure. In the three nonsurvivors there was no reduction in the serum C3 or immunoglobulin levels prior to @entity3 . These data do not support a role for C3 or the immunoglobulins in the pathogenesis of @entity1 . On the contrary, the behavior of these substances during severe @entity4 is more consistent with protective host defense functions.

title: Sequential serum complement (C3) and immunoglobulin levels in shock/ XXXX @entity0 developing @entity1 .

answer: @entity2


abstract: The complement system has been implicated in the physiopathology of @entity5 . Since infection is a major cause of @entity3 in @entity2 @entity0 , we examined daily serum C3 and immunoglobulin levels in all victims of major @entity2 during a 3-month interval. Sixteen @entity0 developed acute systemic @entity4 3-15 days after admission. For all variables the lowest values occurred shortly after hospital admission, during or just after fluid resuscitation. Thereafter, the serum C3 and immunoglobulin concentrations gradually returned to the normal ranges, despite the onset of fulminant systemic @entity4 . Except for IgM, the occurrence of @entity6 during @entity4 did not affect the recovery patterns of the measured variables. In the five @entity0 experiencing @entity6 , serum IgM dropped transiently but resumed its normalization trend after the restoration of adequate perfusion pressure. In the three nonsurvivors there was no reduction in the serum C3 or immunoglobulin levels prior to @entity3 . These data do not support a role for C3 or the immunoglobulins in the pathogenesis of @entity1 . On the contrary, the behavior of these substances during severe @entity4 is more consistent with protective host defense functions.

title: Sequential serum complement (C3) and immunoglobulin levels in shock/ @entity2 XXXX developing @entity1 .

answer: @entity0


abstract: BACKGROUND: @entity12 deficiency is seen in @entity0 with @entity3 ( @entity3 ) and @entity3 . However, the spectrum of the disease has recently expanded to include a milder phenotype. OBJECTIVE: We analyzed a 4-year-old @entity0 who was initially given the diagnosis of selective @entity9 (SIgAD) based on immunoglobulin serum levels without any @entity7 , @entity8 , @entity6 , @entity5 or @entity4 . The @entity0 was found to be @entity2 ; however, the clinical course was not serious. He produced antiviral antibodies. METHODS: We performed lymphocyte phenotyping, quantification of T cell receptor excision circles (TRECs) and kappa deleting recombination excision circles (KRECs), an analysis of target sequences of @entity12 , a whole-genome SNP array, an in vitro V(D)J recombination assay, a spectratype analysis of the CDR3 region and a flow cytometric analysis of the bone marrow. RESULTS: Lymphocyte phenotyping demonstrated that the ratio of CD4+ to CD8+ T cells was inverted and the majority of CD4+T cells expressed CD45RO antigens in addition to the almost complete lack of B cells. Furthermore, both TRECs and KRECs were absent. Targeted DNA sequencing and SNP array revealed that the @entity0 carried a deletion of @entity10 and @entity11 genes on the paternally-derived chromosome 11, and two maternally-derived novel @entity10 missense mutations ( @entity13 , @entity14 ). In vitro analysis of recombination activity showed that both @entity10 mutant proteins had low, but residual function. CONCLUSIONS: The current case further expands the phenotypic spectrum of mild presentations of @entity1 , and suggests that TRECs and KRECs are useful markers for detecting hidden severe, as well as mild, cases.

title: XXXX Deficiency May Present Clinically as Selective IgA Deficiency.

answer: @entity10


abstract: The pharmacokinetics of recombinant @entity0 tissue-type plasminogen activator (rt-PA) were studied in 20 subjects during and after its i.v. infusion at three different rates (5.6, 8.3, and 10 micrograms/kg/min). Steady-state plasma concentrations of 0.9 to 1.6 micrograms/ml were reached. The plasma disappearance curves of rt-PA (both antigen and activity) after cessation of infusion were approximated by a sum of two exponential terms and the turnover of rt-PA was represented by a two-compartment mammillary model with peripheral (liver) elimination. The fractional efflux rate constant from the central compartment was 0.10 per min and the fractional catabolic rate constant about 0.02 per min. After cessation of infusion the initial half-life of the drug in plasma was 6 min. @entity1 levels were measured by a clotting rate assay and by @entity2 precipitation. Infusion of rt-PA at 10 micrograms/kg/min for 30 min did not cause systemic @entity1 breakdown. Infusion of 5.6 micrograms/kg/min for 90 min was associated with a decrease of @entity1 to 62% of the preinfusion value (4.5 g/l) as measured with the clotting rate assay, but only 2% was recovered as incoagulable @entity1 -fibrin degradation products. Infusion of 8.3 micrograms/kg/min for 90 min resulted in a decrease of @entity1 to 45% of the preinfusion level (2.5 g/l) and generation of 8.5% @entity1 -fibrin degradation products. @entity1 assays with the @entity2 method showed a much less extensive decrease of @entity1 . This extent of systemic fibrinolytic activation and @entity1 breakdown at high infusion rates and prolonged durations is compatible with that anticipated from the kinetic parameters of the activation of plasminogen by rt-PA.

title: Pharmacokinetics and systemic fibrinogenolytic effects of recombinant XXXX tissue-type plasminogen activator (rt-PA) in @entity0 .

answer: @entity0


abstract: The pharmacokinetics of recombinant @entity0 tissue-type plasminogen activator (rt-PA) were studied in 20 subjects during and after its i.v. infusion at three different rates (5.6, 8.3, and 10 micrograms/kg/min). Steady-state plasma concentrations of 0.9 to 1.6 micrograms/ml were reached. The plasma disappearance curves of rt-PA (both antigen and activity) after cessation of infusion were approximated by a sum of two exponential terms and the turnover of rt-PA was represented by a two-compartment mammillary model with peripheral (liver) elimination. The fractional efflux rate constant from the central compartment was 0.10 per min and the fractional catabolic rate constant about 0.02 per min. After cessation of infusion the initial half-life of the drug in plasma was 6 min. @entity1 levels were measured by a clotting rate assay and by @entity2 precipitation. Infusion of rt-PA at 10 micrograms/kg/min for 30 min did not cause systemic @entity1 breakdown. Infusion of 5.6 micrograms/kg/min for 90 min was associated with a decrease of @entity1 to 62% of the preinfusion value (4.5 g/l) as measured with the clotting rate assay, but only 2% was recovered as incoagulable @entity1 -fibrin degradation products. Infusion of 8.3 micrograms/kg/min for 90 min resulted in a decrease of @entity1 to 45% of the preinfusion level (2.5 g/l) and generation of 8.5% @entity1 -fibrin degradation products. @entity1 assays with the @entity2 method showed a much less extensive decrease of @entity1 . This extent of systemic fibrinolytic activation and @entity1 breakdown at high infusion rates and prolonged durations is compatible with that anticipated from the kinetic parameters of the activation of plasminogen by rt-PA.

title: Pharmacokinetics and systemic fibrinogenolytic effects of recombinant @entity0 tissue-type plasminogen activator (rt-PA) in XXXX .

answer: @entity0


abstract: Five subjects exercised with the knee extensor of one limb at work loads ranging from 10 to 60 W. Measurements of pulmonary @entity1 uptake, heart rate, leg blood flow, blood pressure and femoral arterial-venous differences for @entity1 and @entity2 were made between 5 and 10 min of the exercise. Flow in the femoral vein was measured using constant infusion of saline near 0 degrees C. Since a cuff was inflated just below the knee during the measurements and because the hamstrings were inactive, the measured flow represented primarily the perfusion of the knee extensors. Blood flow increased linearly with work load right up to an average value of 5.7 l @entity3 . Mean arterial pressure was unchanged up to a work load of 30 W, but increased thereafter from 100 to 130 mmHg. The femoral arterial-venous @entity1 difference at maximum work averaged 14.6% (v/v), resulting in an @entity1 uptake of 0.80 l @entity3 . With a mean estimated weight of the knee extensors of 2.30 kg the perfusion of maximally exercising skeletal muscle of @entity0 is thus in the order of 2.5 l kg-1 @entity3 , and the @entity1 uptake 0.35 l kg-1 @entity3 . Limitations in the methods used previously to determine flow and/or the characteristics of the exercise model used may explain why earlier studies in @entity0 have failed to demonstrate the high perfusion of muscle reported here. It is concluded that muscle blood flow is closely related to the @entity1 demand of the exercising muscles. The hyperaemia at low work intensities is due to vasodilatation, and an elevated mean arterial blood pressure only contributes to the linear increase in flow at high work rates. The magnitude of perfusion observed during intense exercise indicates that the vascular bed of skeletal muscle is not a limiting factor for @entity1 transport.

title: Maximal perfusion of skeletal muscle in XXXX .

answer: @entity0


abstract: OBJECTIVE: This study aimed to evaluate the contribution of work, non-work and individual factors to @entity1 with regard to gender-related differences, and to clarify the mediating role that @entity3 plays in these dynamics in Canada from 1994 to 2008 using the Canadian National Population Health Survey (NPHS). DESIGN: Longitudinal. SETTINGS: The NPHS is a randomised longitudinal cohort study with biennial interviews of the Canadian adult population from 18 to 64. @entity0 : 5925 non-obese workers in cycle 1 (49% were @entity0 ). MEASUREMENTS: @entity1 was measured using the body mass index (BMI), with a threshold of BMI >30   kg/m(2). BMI was corrected in accordance with the recommendations of Connor Gorber et al to adjust for gender bias in responses. RESULTS: Of the work characteristics evaluated, only decision authority was associated with @entity1 for @entity0 but not for @entity0 . Living as a couple, @entity0 -related strains, psychotropic drug use, @entity2 , being physically inactive and low @entity3 were @entity1 risk factors but were not moderated by gender. Overall, @entity3 did not mediate the associations that work factors have on @entity1 . CONCLUSIONS: Our study suggests that @entity0 and @entity0 differ little in the extent to which work, non-work and individual factors predict @entity1 . However, for @entity0 , the level of decision authority is associated with a lower @entity1 risk. In addition, @entity3 did not mediate the contribution of work factors and actually seems, contrary to expectations, to decrease the @entity1 risk when work, non-work and individual factors are taken into account.

title: Work and non-work stressors, XXXX and @entity1 : evidence from a 14-year study on Canadian workers.

answer: @entity3


abstract: OBJECTIVE: This study aimed to evaluate the contribution of work, non-work and individual factors to @entity1 with regard to gender-related differences, and to clarify the mediating role that @entity3 plays in these dynamics in Canada from 1994 to 2008 using the Canadian National Population Health Survey (NPHS). DESIGN: Longitudinal. SETTINGS: The NPHS is a randomised longitudinal cohort study with biennial interviews of the Canadian adult population from 18 to 64. @entity0 : 5925 non-obese workers in cycle 1 (49% were @entity0 ). MEASUREMENTS: @entity1 was measured using the body mass index (BMI), with a threshold of BMI >30   kg/m(2). BMI was corrected in accordance with the recommendations of Connor Gorber et al to adjust for gender bias in responses. RESULTS: Of the work characteristics evaluated, only decision authority was associated with @entity1 for @entity0 but not for @entity0 . Living as a couple, @entity0 -related strains, psychotropic drug use, @entity2 , being physically inactive and low @entity3 were @entity1 risk factors but were not moderated by gender. Overall, @entity3 did not mediate the associations that work factors have on @entity1 . CONCLUSIONS: Our study suggests that @entity0 and @entity0 differ little in the extent to which work, non-work and individual factors predict @entity1 . However, for @entity0 , the level of decision authority is associated with a lower @entity1 risk. In addition, @entity3 did not mediate the contribution of work factors and actually seems, contrary to expectations, to decrease the @entity1 risk when work, non-work and individual factors are taken into account.

title: Work and non-work stressors, @entity3 and XXXX : evidence from a 14-year study on Canadian workers.

answer: @entity1


abstract: Acute (single exposure), 14-d repeated exposure, 91-d subchronic, and 103-wk chronic @entity4 studies of orally administered (gavage, in @entity5 oil) @entity6 were conducted in male and female Fischer-344 @entity2 and B6C3F1 hybrid @entity1 . A single exposure to 4000 mg/kg was lethal to male and female @entity2 , while a single exposure to a dose as low as 1000 mg/kg was lethal to @entity1 . Fourteen daily exposures to 1000 mg/kg caused death in @entity2 of both sexes, but neither survival nor clinical health were compromised at 500 mg/kg in @entity2 or @entity1 . In the 91-d studies, wherein @entity6 was administered once daily, 5 d/wk, survival was reduced by doses of 500 mg/kg and higher in @entity2 , and by doses of 250 mg/kg and higher in @entity1 . Dose-dependent @entity3 of the liver (hepatocytes), @entity3 of the renal proximal tubules, and lymphoid or myeloid depletion of the spleen, bone marrow, and thymus (mild to severe) were produced by doses of 250 mg/kg or greater of @entity6 in both sexes of @entity2 and @entity1 , although the incidences of these lesions varied considerably by sex and species. Consistent changes in the circulating blood components were not observed, but a mild porphyrinuria was detected at the higher doses. No toxic effects were observed at doses of 125 mg/kg or less. In the 2-yr studies, wherein @entity6 was administered once daily, 5 d/wk, doses of 30 or 60 mg/kg in male @entity1 and 60 or 120 mg/kg in female @entity1 and male and female @entity2 did not produce any evidence of @entity4 . Doses of 60 or 120 mg/kg caused slight (statistically significant at 120 mg/kg; p less than 0.05) increases in the frequencies of male @entity2 with neoplastic nodules of the liver. Increased @entity0 frequencies were not observed in female @entity2 or in male or female @entity1 receiving @entity6 .

title: XXXX responses to acute, subchronic, and chronic oral administrations of @entity6 to rodents.

answer: @entity4


abstract: Acute (single exposure), 14-d repeated exposure, 91-d subchronic, and 103-wk chronic @entity4 studies of orally administered (gavage, in @entity5 oil) @entity6 were conducted in male and female Fischer-344 @entity2 and B6C3F1 hybrid @entity1 . A single exposure to 4000 mg/kg was lethal to male and female @entity2 , while a single exposure to a dose as low as 1000 mg/kg was lethal to @entity1 . Fourteen daily exposures to 1000 mg/kg caused death in @entity2 of both sexes, but neither survival nor clinical health were compromised at 500 mg/kg in @entity2 or @entity1 . In the 91-d studies, wherein @entity6 was administered once daily, 5 d/wk, survival was reduced by doses of 500 mg/kg and higher in @entity2 , and by doses of 250 mg/kg and higher in @entity1 . Dose-dependent @entity3 of the liver (hepatocytes), @entity3 of the renal proximal tubules, and lymphoid or myeloid depletion of the spleen, bone marrow, and thymus (mild to severe) were produced by doses of 250 mg/kg or greater of @entity6 in both sexes of @entity2 and @entity1 , although the incidences of these lesions varied considerably by sex and species. Consistent changes in the circulating blood components were not observed, but a mild porphyrinuria was detected at the higher doses. No toxic effects were observed at doses of 125 mg/kg or less. In the 2-yr studies, wherein @entity6 was administered once daily, 5 d/wk, doses of 30 or 60 mg/kg in male @entity1 and 60 or 120 mg/kg in female @entity1 and male and female @entity2 did not produce any evidence of @entity4 . Doses of 60 or 120 mg/kg caused slight (statistically significant at 120 mg/kg; p less than 0.05) increases in the frequencies of male @entity2 with neoplastic nodules of the liver. Increased @entity0 frequencies were not observed in female @entity2 or in male or female @entity1 receiving @entity6 .

title: @entity4 responses to acute, subchronic, and chronic oral administrations of XXXX to rodents.

answer: @entity6


abstract: OBJECTIVES: To investigate clinical features of @entity1 ( @entity1 ) and their association with risk factors for @entity1 in a genetic risk birth cohort. METHODS: @entity0 from 6 clinical centers in 4 countries positive for HLA- @entity3 -DQ2 or @entity4 -DQ8 were annually screened for @entity5 antibodies (tTGA) and assessed for symptoms by questionnaires. Associations of symptoms with anthropometrics, known risk factors for @entity1 , tTGA levels, and @entity2 in those biopsied were examined. RESULTS: Of 6706 screened @entity0 , 914 developed persistent positive tTGA, 406 underwent biopsies, and 340 had @entity1 . Compared with age-matched tTGA-negative @entity0 , those with persistent tTGA were more likely to have symptoms at 2 (34% vs 19%, P < .001) and 3 years of age (28% vs 19%, P = .009) but not at 4 years (27% vs 21%, NS). Z-scores for height, weight, and BMI did not differ between groups. In @entity0 with persistent tTGA, having >=  1 symptom was associated with family history of @entity1 (odds ratio = 2.59, 95% confidence interval, 1.21-5.57) but not with age, gender, or HLA- @entity3 -DQ2 homozygosity. At seroconversion, tTGA levels were higher in symptomatic than asymptomatic @entity0 (P < .001), in those from @entity1 families (P < .001), and in US @entity0 (P < .001) but not associated with age, gender, or HLA genotype. tTGA levels correlated with severity of @entity2 both in symptomatic (r = 0.53, P < .001) and asymptomatic @entity0 (r = 0.22, P = .01). CONCLUSIONS: A majority of @entity0 detected with persistent tTGA in screenings are asymptomatic and have normal growth by age 4 years. tTGA levels correlate more strongly with severity of @entity2 in symptomatic as compared with asymptomatic @entity0 .

title: Clinical features of XXXX : a prospective birth cohort.

answer: @entity1


abstract: Although anti- @entity2 drugs have changed the clinical course of @entity1 ( @entity1 ), survival rates and resistance-to-therapy data confirm that about 30% of @entity1 @entity0 fail to respond. The aim of this study was to evaluate the correlations between the development of antidrug antibodies, specific IgG4 antibodies against @entity2 inhibitors, and resistance to therapy in @entity1 @entity0 . This retrospective study involved 129 @entity0 with established @entity1 na  ve to biological agents (98 females and 32 males, mean age 56.7  12.3 years, disease duration 6.3  1.2 years, baseline Disease Activity Score [DAS]-28 3.2-5.6) who received treatment with anti- @entity2 agents after the failure of conventional disease-modifying antirheumatic drugs (32 received infliximab [IFX], 58 etanercept [ETN], and 39 adalimumab [ADA]). After 6 months of treatment, the @entity0 were classified as being in remission (DAS28 <2.6), having low disease activity (LDA; DAS28 2.6-3.2), or not responding (NR: DAS28 >3.2). The @entity0 were also tested for serum antidrug antibodies and IgG4 antibodies against @entity2 inhibitors. After 24 weeks of treatment, 38% of the ETN-treated @entity0 and 28% of those treated with ADA had injection-site reactions; the rate of systemic reactions in the IFX group was 25%. The differences among the three groups were not statistically significant (P=0.382; ETN versus ADA P=0.319). The percentages of @entity0 with adverse events stratified by drug response were: LDA 8% and NR 18% in the ADA group; in remission 3%, LDA 22%, and NR 10% in the ETN group; and LDA 6% and NR 16% in the IFX group (P=0.051). The percentages of patients with antidrug antibodies were: ADA 33.3%, ETN 11.5%, and IFX 10.3% (P=0.025; ADA versus ETN P=0.015). The percentages of patients with IgG4 antibodies were: ADA 6%, ETN 13%, and IFX 26% (P=0.017; ADA versus ETN P=0.437). Associations between antidrug antibodies, specific IgG4 antibodies, and adverse reactions were not significant for any of the three drugs. IgG4 levels were higher in the ADA group than in the other two groups, and higher in the @entity0 with worse DAS28 (NR) and in those experiencing adverse events. These data suggest a possible association between IgG4 levels and worse DAS28 (r (2)=5.8%, P=0.011). The presence of specific IgG4 antibodies against @entity2 in @entity0 with @entity1 might affect the drugs' activity. @entity0 with injection-site reactions and IgG4 against ETN may show a decreased response.

title: Antidrug antibodies against XXXX -blocking agents: correlations between disease activity, hypersensitivity reactions, and different classes of immunoglobulins.

answer: @entity2


abstract: PURPOSE: @entity2 are usually the result of high-energy @entity1 , and @entity3 after a @entity2 is an often complication. Though organic pathologies can be the reason for @entity3 , @entity4 following a @entity1 may also be linked to sexual problems. We aimed to evaluate the frequency of @entity3 , and help these @entity0 with their usually undisclosed sexual problems, and offer them support. MATERIALS AND METHODS: During a 4-year period, between June 2008 and May 2012, 40 male @entity0 (out of 57) with a mean age of 42.6  years (range 18-65  years) were evaluated retrospectively. @entity0 having organic pathologies (vascular, neural, and urogenital system pathologies) were excluded from the study. @entity0 were requested to complete the Arizona Sexual Experience Scale (ASEX), which is a 5-item self-evaluation scale. According to the results of the questionnaire, @entity0 needing supportive treatment were referred to the psychiatry department. RESULTS: Twenty-two @entity0 (55  %) scored 10 points or less in the ASEX questionnaire (normal). Eighteen @entity0 (45  %) had 11 points or more (can be problematic). Four of these 18 @entity0 had a score of 19 points or more (needing psychiatric evaluation). @entity0 with a score of >= 19 points, for any one item with a score of 5 or 6 points, or any three or more items with a score of 4 points were considered to have a high probability of @entity3 after psychiatric evaluation. CONCLUSION: The frequency of @entity3 in pelvic @entity2 @entity0 was tested, and the need for investigating @entity3 is stressed. This study attracts attention to @entity3 and the necessity of referring these @entity0 to the related clinics, for treatment. LEVEL OF EVIDENCE: Retrospective case series.

title: @entity3 of male, after XXXX .

answer: @entity2